A phase I/II trial of gemcitabine (Gemzar) plus ABI-007 (ABRAXANE) in patients with advanced metastatic pancreatic cancer

Trial Profile

A phase I/II trial of gemcitabine (Gemzar) plus ABI-007 (ABRAXANE) in patients with advanced metastatic pancreatic cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 02 Dec 2016 Results (n=37) of PET response and survival analysis presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 04 Oct 2011 Status changed from active, no longer recruiting to completed.
    • 04 Oct 2011 Results were published in the online version of the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top